vestimИзвестия Национальной академии наук Беларуси. Серия медицинских наукProceedings of the National Academy of Sciences of Belarus, Medical series1814-60232524-2350The Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"vestim-398Research ArticleКЛИНИЧЕСКАЯ И ЭКСПЕРИМЕНТАЛЬНАЯ МЕДИЦИНАCLINICAL AND EXPERIMENTAL MEDICINEВЛИЯНИЕ КОМБИНАЦИИ УРСОДЕЗОКСИХОЛЕВОЙ КИСЛОТЫ И ПЕНТОКСИФИЛЛИНА НА ТЕЧЕНИЕ ЭКСПЕРИМЕНТАЛЬНОГО ФИБРОЗА ПЕЧЕНИINFLUENCE OF THE COMBINATION OF URSODEOXYCHOLIC ACID AND PENTOXYPHILLINE ON EXPERIMENTAL LIVER FIBROSISБелоновскаяЕ. Б.BelonovskayaE. B.

науч. сотрудник

БЛК-50, 230030

 

Researcher

BLK-50, 230030

ms.belonovskaya@yandex.ruНарутаЕ. Е.NarutaE. E.

канд. биол. наук, вед. науч. сотрудник

БЛК-50, 230030

Ph. D. (Biol.), Leading researcher

BLK-50, 230030

naruta@list.ruЛукивскаяО. Я.LukivskayaO. Y.

канд. биол. наук, вед. науч. сотрудник

БЛК-50, 230030

Ph. D. (Biol.), Leading researcher

BLK-50, 230030

vu.buko@tut.byКазючицО. А.KazyuchitsO. A.

канд. биол. наук

ул. акад. Купревича, 5/3, 220141

Ph. D. (Biol.)

5/3, Ac. Kuprevich Str., 220141

ifb@academpharm.byБукоВ. У.BukoV. U.

д-р биол. наук, профессор, заведующий отделом

БЛК- 50, 230030

D. Sc. (Biol.), Professor, Head of the Department

BLK-50, 230030

vu.buko@tut.byИнститут биохимии биологически активных соединений НАН Беларуси, ГродноInstitute of Biochemistry of Biologically Active Compounds of the National Academy of Sciences of Belarus, GrodnoРеспубликанское производственное унитарное предприятие «АКАДЕМФАРМ», МинскState Enterprise “ACADEMPHARM”, Minsk201709122017043140Copyright © Белоновская Е.Б., Нарута Е.Е., Лукивская О.Я., Казючиц О.А., Буко В.У., 20172017Белоновская Е.Б., Нарута Е.Е., Лукивская О.Я., Казючиц О.А., Буко В.У.Belonovskaya E.B., Naruta E.E., Lukivskaya O.Y., Kazyuchits O.A., Buko V.U.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestimed.belnauka.by/jour/article/view/398

Фиброз печени является типичным ответом на хроническое воспаление печеночной ткани вследствие различных заболеваний. Фиброз – это динамический процесс, приводящий к тяжелым осложнениям: развитию цирроза, гепатоцеллюлярной карциноме, печеночной недостаточности. Учитывая социальную значимость проблемы, поиск новых, более эффективных препаратов, обладающих гепатозащитным и антифибротическим действием при фиброзе печени, является актуальной задачей.

Целью исследования было изучение влияния готовой лекарственной формы (ГЛФ) на основе комбинации урсодезоксихолевой кислоты (УДХК) и пентоксифиллина (ПТФ) на развитие CCl4 -индуцированного фиброза печени у крыс. Установлено, что введение ГЛФ в дозах, эквивалентных 40 и 80 мг/кг УДХК, в условиях токсического воздействия сопровождалось ослаблением активности маркерных ферментов, общего и связанного билирубина, снижением содержания оксипролина в печени, коллагена III, ламинина и TNF-α по сравнению с аналогичными показателями у крыс опытной группы, не получавших препараты, а также способствовало снижению уровня гиалуроновой кислоты, проколлагена III и TGF-β1 , причем действие высокой дозы ГЛФ, в отличие от малой, было более выраженным.

Таким образом, полученные данные свидетельствуют о том, что ГЛФ обладает достаточно высоким терапевтическим потенциалом, проявляя противофиброзное, противовоспалительное и гепатопротективное действие в условиях токсического фиброза печени. 

Hepatic fibrosis is a common result of different chronic liver diseases. Fibrosis is a dynamic process which can progress to complication, including cirrhosis, hepatocellular carcinoma, and liver failure. Considering the significance of problem, the search for a new effective substance with hepatoprotective and antifibrotic effects on liver fibrosis is an actual task.

The aim of the study was to investigate the influence of fixed-dose combination (FDC) containing ursodeoxycholic acid (UDCA) 350 mg and pentoxifylline (PTX) 150 mg on the development of carbon tetrachloride (CCL4 )-induced liver fibrosis in rats. The obtained results showed that FDC effectively reduced elevated serum markers enzyme activities, the hepatic hydroxyproline content, decreased levels of proinflammatory and profibrogenic cytokines. The histopathological analysis showed that FDC alleviated the severity of liver fibrosis induced by CCl4 . A high dose of FDC had the most positive effect.

Thus, the obtained results suggested that FDC has a sufficiently high therapeutic potential, demonstrating antifibrotic, antiinflammatory and hepatoprotective activities on experimental liver fibrosis. 

фиброзпеченьурсодезоксихолевая кислотапентоксифиллинкомбинацияцитокиныкрысыfibrosisliverursodeoxycholic acidpentoxifyllinecombinationcytokinesratsReferencesBataller, R. Liver fibrosis / R. Bataller, D.A. Brenner // J. Clin. Invest. – 2005. – Vol. 115. – P. 209–218.Bataller R., Brenner D. A. Liver fibrosis. Journal of Clinical Investigation, 2005, vol. 115, pp. 209–218. DOI: 10.1172/ JCI24282A comparison of fibrosis progression in chronic liver diseases / T.A. Poynard [et al.] // J. Hepatol. – 2003. – Vol. 38. – P. 257–265.Poynard T. A., Mathurin P., Lai C. L., Guyader D., Poupon R. A comparison of fibrosis progression in chronic liver diseases. Journal of Hepatology, 2003, vol. 38, pp. 257–265.Mormone, E. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches / E. Mormone, J. George, N. Nieto // Chem. Biol. Interac. – 2011. – Vol. 193, N 3. – P. 225–231.Mormone E., George J., Nieto N. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chemico-Biological Interactions, 2011, vol. 193, no. 3, pp. 225–231. DOI: http://dx.doi.org/101155/2015/943497Liver cirrhosis mortality in Europe, with special attention to Central and Eastern Europe / W.A. Zatonsky [et al.] // Eur. Addict. Res. – 2010. – Vol. 16, N 4. – P. 193–201.Zatonsky W. A., Sulkovska U., Manczuk M. Liver cirrhosis mortality in Europe, with special attention to Central and Eastern Europe. European Addiction Research Journal, 2010, vol. 16, no. 4, pp. 193–201. DOI: 1159/000317248Смертность в Республике Беларусь за 2014–2015 гг. : офиц. стат. сб. за 2014–2015 гг. / Респ. науч.-практ. центр мед. технологий, информатизации, управления и экономики здравоохранения. – Минск : Респ. науч. мед. б-ка, 2016. – 208 с.Mortality in Repeblic of Belarus. An official statistics collection, 2014–2015. Minsk, Respublikanskaya meditsinskaya nauchnaya biblioteka [Republican Scientific Medical Library], 2016. 208 p. (in Russian).Ивашкин, В.Т. Лечение осложнений цирроза печени / В.Т. Ивашкин, М.В. Маевская. – М. : Литтерра, 2011. – 64 с.Ivashkin V. Т., Maevskaja M. V. Treatment of liver cirrhosis complications. Мoscow, Litterra Publ., 2011, 64 p. (in Russian).Parsons, C.J. Molecular mechanisms of hepatic fibrogenesis / C.J. Parsons, M. Takashima, R.A. Rippe // J. Gastroenterol. Hepatol. – 2007. – Vol. 22, iss. 1. – P. 79–84.Parsons C. J., Takashima M., Rippe R. A. Molecular mechanisms of hepatic fibrogenesis. Journal of Gastroenterology and Hepatology, 2007, vol. 22, suppl. 1, pp. 79–84. DOI: 10.1111/j.1440–1746.2006.04659.xLemos, Q.T. Angiogenesis and experimental hepatic fibrosis / Q.T. Lemos, Z.A. Andrade // Mem. Inst. Oswaldo Cruz. – 2010. – Vol. 105, iss. 5. – P. 611–614.Lemos Q. T., Andrade Z. A. Angiogenesis and experimental hepatic fibrosis. Memorias do Instituto Oswaldo Cruz, 2010, vol. 105, no. 5, pp. 611–614.Tsochatzis, E.A. Liver cirrhosis / E.A. Tsochatzis, J. Bosch, A.K. Burroughs // Lancet. – 2014. – Vol. 383. – P. 1749– 1761.Tsochatzis E. A., Bosch J., Burroughs A. K. Liver cirrhosis. Lancet, 2014, vol. 383, pp. 1749–1761. DOI: 10.1016/ S0140–6736(14)60121–5Bonis, P.A. Is liver fibrosis reversible? / P.A. Bonis, S.L. Friedman, M.M. Kaplan // N. Engl. J. Med. – 2001. – Vol. 344. – P. 452–454.Bonis P. A., Friedman S. L., Kaplan M. M. Is liver fibrosis reversible? The New England Journal of Medicine, 2001, vol. 344, pp. 452–454. DOI: 10.1136/gut. 46.4.443Liaw, Y.F. Reversal of cirrhosis: an achievable goal of hepatitis B antiviral therapy / Y.F. Liaw // J. Hepatol. – 2013. – Vol. 59. – P. 880–881.Liaw Y.F. Reversal of cirrhosis: an achievable goal of hepatitis B antiviral therapy. Journal of Hepatology, 2013, vol. 59, pp. 880–881. DOI: https://doi.org/10.3904/kjim.2016.268Ellis, E.L. Clinical evidence for the regression of liver fibrosis / E.L. Ellis, D.A. Mann // J. Hepatol. – 2012. – Vol. 56, N5. – P. 1171–1180.Ellis E. L., Mann D. A. Clinical evidence for the regression of liver fibrosis. Journal of Hepatology, 2012, vol. 56, no. 5, pp. 1171–1180.Kang, Q. Curcumin suppresses expression of low-density lipoprotein (LDL) receptor, leading to the ingibition of LDL-induced activation of hepatic stellate cells / Q. Kang, A. Chen // Br. J. Pharmacol. – 2009. – Vol. 157, iss. 8. – P. 1354– 1367.Kang Q., Chen A. Curcumin suppresses expression of low-density lipoprotein (LDL) receptor, leading to the ingibition of LDL-induced activation of hepatic stellate cells. British Journal of Pharmacology, 2009, vol. 157, no. 8, pp. 1354–1367. DOI: 10.1111/j.1476–5381.2009.00261.xHirschfield, G.M. Progress in the genetics of primary biliary cirrhosis / G.M. Hirschfield, P. Invernizzi // Semin. Liver Dis. – 2011. – Vol. 31, iss. 2. – P. 147–156.Hirschfield G. M., Invernizzi P. Progress in the genetics of primary biliary cirrhosis. Seminars in Liver Disease, 2011, vol. 31, no. 2, pp. 147–156.Risk factors and prediction of long-term outcome in primary biliary cirrhosis / H. Ishibashi [et al.] // Intern. Med. – 2011. – Vol. 50, iss. 1. – P. 1–10.Ishibashi H., Komori A., Shimoda S., Ambrosini Y. M., Gershwin M. E., Nakamura M. Risk factors and prediction of long-term outcome in primary biliary cirrhosis. Internal Medicine, 2011, vol. 50, no. 1, pp. 1–10.Эффективность урсодезоксихолевой кислоты в лечении больных холестатической формой алкогольной болезни печени и первичным билиарным циррозом / Е.Н. Широкова [и др.] // РЖГГК. – 2007. – №3. – С. 52–58.Shirokova E. N., Kuznetcova Ye. L., Mayevskaya M. V. Effective of ursodeoxycholic acid acid in the treatment of patients with cholestatic form of alcoholic liver disease and primary biliary cirrhosis. Russian Journal of Gastroenterology, Hepatology, Coloproctology, 2007, no. 3, pp. 52–58 (in Russian).High dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis / D.M. Harnois [et al.] // Am. J. Gastroenterol. – 2001. – Vol. 96. – P. 1558–1562.Harnois D. M., Angulo P., Jorgensen R. A., Larusso N. F., Lindor K. D. High dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. American Journal of Gastroenterology, 2001, vol. 96, pp. 1558–1562.Xiang, Z. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis / Z. Xiang, Y.P. Chen, K.F. Ma // BMC Gastroenterol. – 2013. – Vol. 13, N 1. – P. 140.Xiang Z., Chen Y. P., Ma K. F. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis. BMC Gastroenterology, 2013, vol. 13, no. 1, p. 140. DOI: 10.1186/1471–230X-13–140Sha, M. The efficacy of pentoxifylline in the treatment of vascular dementia / M. Sha, C. Callahan // Alzheimer Dis. Assoc. Disord. – 2003. – Vol. 17, iss. 1. – P. 46–54.Sha M., Callahan C. The efficacy of pentoxifylline in the treatment of vascular dementia. Alzheimer Disease and Associated Disorders, 2003, vol. 17, no. 1, pp. 46–54. DOI: 10.1097/00002093–200301000–00006Хронические цереброваскулярные расстройства – современные подходы к лечению / П.Р. Камчатнов [и др.] // Рус. мед. журн. – 2008. – Т. 16, №6. – С. 358–361.Kamchatnov P. R., Radysh B., Glushkov K. S., B. Chugunov A. V. Chronic cerebrovascular disorders – modern approaches to treatment. Russkij medicinskij zhurnal [Russian Medical Journal], 2008, vol. 16, no. 6, pp. 358–361 (in Russian).Pentoxifylline in the treatment of radiation-induced fibrosis / P. Ocunieff [et al.] // J. Clin. Oncol. – 2004. – Vol. 22, iss. 11. – P. 2207–2213.Ocunieff P., Augustine E., Hicks J., Cornelison T. L., Altemus R. M., Naydich B. G., Ding I., Huser A. K., Abraham E. H., Smith J. J., Coleman N., Gerber L. H. Pentoxifylline in the treatment of radiation-induced fibrosis. Journal of Clinical Oncology, 2004, vol. 22, no. 11, pp. 2207–2213.O’Shea, R.S. Alcoholic liver desease / R.S. O’Shea, S. Dasarathy, A.J. McCullough / J. Hepatol. – 2010. – Vol. 51, N 1. – P. 307–328.O’Shea R. S., Dasarathy S., McCullough A. J. Alcoholic liver disease. Journal of Hepatology, 2010, vol. 51, no. 1, pp. 307–328. DOI: 10.1002/hep.23258Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis / S.K. Satapathy [et al.] // Am. J. of Gastroenterol. – 2004. – Vol. 99, iss. 10. – P. 1946–1952.Satapathy S. K., Garg S., Chauhan R., Sakhuja P., Malhotra V., Sharma B. C. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. American Journal of Gastroenterology, 2004, vol. 99, no. 10, pp. 1946–1952. DOI: 10.1111/j.1440–1746.2006.04756.xRokey, D.C. Antifibrotic therapy in chronic liver desease / D.C. Rokey // Clin. Gastroenterol. Hepatol. – 2005. – Vol. 3, N2. – P. 95–107.Rokey D. C. Antifibrotic therapy in chronic liver desease. Clinical Gastroenterology and Hepatology, 2005, vol. 3, no. 2, pp. 95–107.Автандилов, Г.Г. Введение в количественную патологическую морфологию / Г.Г. Автандилов. – М. : Медицина, 1980. – 216 с.Avtandilov G. G. Introduction to quantitative pathological morphology. Мoscow, Меdicine, 1980. 216 p. (in Russian).An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis / J.J. Cho [et al.] // J. Gastroenterol. – 2000. – Vol. 118, N 6. – P. 1169–1178.Cho J. J., Hocher B., Herbst H., Jia J. D., Ruehl M., Hahn E. G., Riecken E. O., Schuppan D. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Journal of Gastroenterology, 2000, vol. 118, no. 6, pp. 1169–1178. DOI: http://dx.doi.org/10.1016/S0016–5085(00)70370–2Protective effects of norursodeoxycholic acid versus ursodeoxycholic acid on thioacetamide-induced rat liver fibrosis / V.U. Buko [et al.] // J. Clin. Exp. Hepatol. – 2014. – Vol. 4, N 4. – P. 293–301.Buko V. U., Lukivskaya O. Y., Naruta E. E., Belonovskaya E. B., Tauschel H. D. Protective effects of norursodeoxycholic acid versus ursodeoxycholic acid on thioacetamide-induced rat liver fibrosis. Journal of Clinical and Experimental Hepatology, 2014, vol. 4, no. 4, pp. 293–301. DOI: 10.1016/j.jceh.2014.02.001Ursodeoxycholic acid treatment improves hepatocyte ultrastructure in rat liver fibrosis / N. Mas [et al.] // World J. Gastroenterol. – 2008. – Vol. 14, N 7. – P. 1108–1111.Mas N., Tasci I., Comert B., Ocal R., Mas M. R. Ursodeoxycholic acid treatment improves hepatocyte ultrastructure in rat liver fibrosis. World Journal of Gastroenterology, 2008, vol. 14, no. 7, pp. 1108–1111. DOI: 10.3748/wjg.14.1108Resolution of thioacetamide induced liver fibrosis in rats treated with pentoxifylline / V.U. Buko [et al.] // J. Hepatol. – 2007. – Vol. 46, suppl. 1. – S80.Buko V. U., Popov Y. V., Lis R. E., Zaks J., Schuppan D., Lukivskaya O. Y. Resolution of thioacetamide induced liver fibrosis in rats treated with pentoxifylline. Journal of Hepatology, 2007, vol. 46, suppl. 1, S80.Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary billiary fibrosis // C. Raetsch [et al.] // Gut. – 2002. – Vol. 50, N 2. – P. 241–247.Raetsch C., Jia J. D., Boigk G., Bauer M., Hahn E. G., Riecken E. O., Schuppan D. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary billiary fibrosis. Gut, 2002, vol. 50, no. 2, pp. 241–247.

The authors declare that there are no conflicts of interest present.